
    
      Subjects who meet the criteria for participation in this study receive 2 intravenous
      infusions of MabionCD20® or MabThera® with two weeks interval in combination with
      methotrexate and folic acid. After the treatment period, patients are followed for 24 weeks,
      in order to continue checking safety. Therefore, the total study lasts 48 weeks. There is a
      possibility to repeat treatment after 6 months of the first infusions if subject meets the
      retreatment criteria.
    
  